Vol.4 No.4 – 12 : IL‑17F and IL- 23 gene polymorphism in patients with acute myeloid leukemia, an Egyptian study.
By :
*Aml S Nasr(M.D)1, Hoda M El Azizy (M.D) 2, Noha M El Husseiny(M.D) 3 ,Samar S Youssef (PhD)4
1 Clinical Pathology Department , Faculty of Medicine, Cairo University, Egypt.
2 Medical biochemistry Department, Faculty of Medicine, Cairo University, Egypt.
3 Internal medicine Department , Cairo University, Egypt.
4Microbial biotechnology Department, National Research Center, Giza, Egypt.
Abstract
Background: Acute myeloid leukemia (AML) is a highly fatal disease occurring due to proliferation and accumulation of myeloid progenitor cells. Th17 cells had been claimed by many studies to play a role in the development of AML. Aim Of work: This work aimed to detect possible role of IL 17 F and IL 23 gene polymorphisms in pathogensis of AML ,relation to prognosis and response to treatment. Subjects , materials and methods: This study was done on 68 patients with newly diagnosed AML (as a patient group) ,together with 56 matched healthy volunteers( control group). IL 17 F and IL 23 gene polymorphisms were genotyped by real time polymerase chain reaction(Real time PCR). Results: No significant differences were detected between patients and controls in respect to IL 17 genotype distribution , there was statistically significant differences between patients and controls regarding IL 23 genotype distribution. No statistically significant relation was found beween interleukin 17 and interleukin 23 and any of the bad prognostic markers. Conclusion: We concluded that IL23 gene polymorphism could be considered as independent risk factor in the pathogenesis of AML ,while we could not prove that IL 17 gene polymorphism has a role in the development of AML.
IL‑17F and IL- 23 gene polymorphism in patients with acute myeloid leukemia, an Egyptian study (1)
Leave a Reply
Want to join the discussion?Feel free to contribute!